MedPath

Merck, Inc.

🇵🇭Philippines
Ownership
Subsidiary
Employees
-
Market Cap
$295.3B
Website
http://www.merck.ph
Clinical Trials
Related News

Gut Hormone Profiling in Obese Patients With Type 2 Diabetes (MK-0000-134)

Completed
Conditions
Diabetes Mellitus Type 2
Obesity, Morbid
First Posted Date
2009-08-13
Last Posted Date
2016-01-20
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
22
Registration Number
NCT00957957

Safety, Radiation Dosimetry, Biokinetics, and Effectiveness of [18F]MK3328 (MK-3328-001)

Phase 1
Completed
Conditions
Alzheimer's Disease
Interventions
Drug: [18F]MK-3328
First Posted Date
2009-08-07
Last Posted Date
2015-11-03
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
19
Registration Number
NCT00954538

Pharmacokinetics of Vaniprevir (MK-7009) and Hepatitis C Virus RNA Levels After Vaniprevir Treatment (MK-7009-029)

Phase 1
Terminated
Conditions
Chronic Hepatitis C Infection
Interventions
Drug: Vaniprevir
First Posted Date
2009-08-07
Last Posted Date
2018-10-18
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
3
Registration Number
NCT00954993

Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)

Phase 1
Terminated
Conditions
Neoplasms
Interventions
Biological: Robatumumab
Biological: Trastuzumab
Drug: Carboplatin
Drug: Epirubicin
Drug: Everolimus
Drug: Gemcitabine
Biological: Cetuximab
Drug: 5-FU
Drug: Erlotinib
Drug: Paclitaxel
Drug: Cisplatin
Drug: Irinotecan
Drug: Folinic Acid
First Posted Date
2009-08-07
Last Posted Date
2018-08-24
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
15
Registration Number
NCT00954512

Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)

Phase 3
Completed
Conditions
Chemotherapy-induced Nausea and Vomiting (CINV)
Interventions
Drug: aprepitant
Drug: granisetron
Drug: dexamethasone
First Posted Date
2009-08-06
Last Posted Date
2017-06-02
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
421
Registration Number
NCT00952341

A Study of V260 in Healthy Chinese Adults, Children and Infants (V260-028)(COMPLETED)

Phase 1
Completed
Conditions
Rotavirus Gastroenteritis
Interventions
Biological: Rotavirus Vaccine, Live, Oral, Pentavalent
First Posted Date
2009-08-06
Last Posted Date
2015-11-01
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
144
Registration Number
NCT00953056

A Study to Assess the Bioequivalence of Famotidine Chewable Tablets and Film-Coated Tablets (0208-144)

Phase 1
Completed
Conditions
Heartburn
Interventions
Drug: Famotidine FCT
Drug: Famotidine CT
First Posted Date
2009-07-24
Last Posted Date
2017-03-10
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
30
Registration Number
NCT00945750

A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)

Phase 1
Completed
Conditions
Chemotherapy-Induced Nausea and Vomiting
Interventions
Drug: aprepitant 165 mg
First Posted Date
2009-07-24
Last Posted Date
2015-01-28
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
42
Registration Number
NCT00945321

Study of the Bioequivalence of Two Tablet Forms of MK0431 (0431-027)

Phase 1
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: Sitagliptin phosphate anhydrous formulation
First Posted Date
2009-07-23
Last Posted Date
2015-08-19
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
12
Registration Number
NCT00944450

MK0524A Bioequivalence Study (0524A-059)

Phase 1
Completed
Conditions
Dyslipidemia
Interventions
Drug: niacin (+) laropiprant (Source 1)
First Posted Date
2009-07-23
Last Posted Date
2015-06-19
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
188
Registration Number
NCT00944645
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy